BSE List Price : ₹978.20

NSE List Price : ₹988.00

subscription

Category	Times
QIBs	181.2x
HNIs	77.56x
Retail	13.65x
Total : 75.06x

IPO Market Lot(s) Distribution

Application	Lot Size	Shares	Amount
Retail Minimum	1	15	₹14,820
Retail Maximum	13	195	₹192,660
S-HNI Minimum	14	210	₹207,480
S-HNI Maximum	67	1,005	₹992,940
B-HNI Minimum	68	1,020	₹1,007,760

About the Company

Incorporated in 2002, Symbiotec Pharmalab Ltd. is a pharmaceutical and biotechnology company involved in the development and manufacturing of active pharmaceutical ingredients (APIs), nutritional ingredients, and specialty products. The company serves both domestic and international markets, covering regulated as well as emerging geographies.

The company emphasizes research-led manufacturing, stringent quality standards, and sustainable production practices, catering to the pharmaceutical, nutraceutical, and wellness sectors. Its operations are supported by a commitment to supplying high-quality ingredients that meet global regulatory and quality requirements.

With more than 30 years of industry experience, Symbiotec Pharmalab has grown from a laboratory-scale manufacturer of steroidal hormone APIs in 1995 into an industrial-scale, backward-integrated manufacturing platform. The company has obtained approvals from regulatory and quality bodies including the US FDA, EU-GMP, and the Ministry of Food and Drug Safety, Korea, along with other international organizations.

Company Financial Report

_{Amount ₹ in Crores}

Period Ended	Revenue	Expense	PAT	Assets
2024	₹723.33	₹590.99	₹100.06	₹1294.79
2025	₹755.98	₹608.85	₹96.79	₹1579.65
2026	₹872.26	₹709.90	₹109.90	₹1780.79

Company Promoter

Anil Satwani

Kashish Satwani

Sushil Satwani

Satwani Holdings LLP

Know before investing

• • Strengths

  Global expertise in corticosteroid and steroidal-hormone APIs: The company possesses strong expertise and a leading position in the manufacturing of corticosteroid and steroidal-hormone APIs. Its specialized manufacturing capabilities strengthen its presence in the global pharmaceutical ingredients market.

  Integrated and vertically structured manufacturing platform: The company operates a well-invested, multi-scale and vertically integrated manufacturing platform. Its integrated operations are complemented by sustainable manufacturing practices and a track record of regulatory compliance.

• • Risks

  Regulatory and quality compliance exposure: The company’s manufacturing facilities undergo periodic inspections and audits by regulatory authorities as well as customers. Any shortcomings in manufacturing processes or quality controls may lead to regulatory action, reputational concerns, and an adverse impact on business operations and financial performance.

  Significant reliance on export markets: The company derives a substantial share of its revenue from customers located outside India, accounting for 66.67%, 55.19%, 59.97%, and 52.76% of revenue from operations for the three months ended June 30, 2025 and Fiscals 2025, 2024, and 2023, respectively. Failure to effectively manage risks related to international sales could negatively impact overseas revenue and overall financial performance.

Objects of the Issue & Utilisation of proceeds

Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company.

General corporate purposes.

Company  Address

Symbiotec Pharmalab Ltd.
385/2,
Pigdamber, Rau,
Mhow,
Indore, Madhya Pradesh, 453331
Phone: +91 731 667 6405
Email: secretarial@symbiotec.com
Website: http://www.symbiotec.com/

IPO Registrar

MUFG Intime India Pvt. Ltd.
Phone: 022-49186000
Email: symbiotecpharmalab.ipo@in.mpms.mufg.com
Website: https://in.mpms.mufg.com/Initial_Offer/public-issues.html